← Ablatotech Vitals
Nephrology EvidenceDigest

The Role of mRNA Vaccines in Reducing Infection-Related Complications in Dialysis Patients

Nephrology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 8, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Patients receiving dialysis are at increased risk of infection-related complications due to immune dysfunction and frequent healthcare exposure. mRNA vaccines against SARS-CoV-2 have demonstrated the ability to elicit durable humoral responses in peritoneal dialysis patients, potentially reducing infection severity and associated morbidity. While vaccination does not eliminate infection risk, it represents a critical component of infection prevention strategies in this vulnerable population. Ongoing monitoring of vaccine efficacy and breakthrough infections is essential to optimize protection (Quiroga et al., 2022; Levy et al., 2016).

Clinical bottom line

Patients receiving dialysis are at increased risk of infection-related complications due to immune dysfunction and frequent healthcare exposure. mRNA vaccines against SARS-CoV-2 have demonstrated the ability to elicit durable humoral responses in peritoneal dialysis patients, potentially reducing infection severity and associated morbidity. While vaccination does not eliminate infection risk, it represents a critical component of infection prevention strategies in this vulnerable population. Ongoing monitoring of vaccine efficacy and breakthrough infections is essential to optimize protection (Quiroga et al., 2022; Levy et al., 2016).

What the evidence shows

Quiroga et al. (2022) provide evidence that patients on peritoneal dialysis mount a robust and sustained antibody response following SARS-CoV-2 mRNA vaccination. Their longitudinal study shows maintained humoral immunity over several months, suggesting effective immunogenicity despite underlying immunocompromise.

Levy et al. (2016) review infection complications in end-stage kidney disease (ESKD), highlighting the high burden of infectious morbidity and mortality in dialysis patients, underscoring the importance of preventive measures including vaccination.

Yu et al. (2025) describe varicella-zoster virus vaccine-related ocular complications, emphasizing the need for vigilance regarding vaccine safety profiles in immunocompromised hosts, including dialysis patients.

Melexopoulou et al. (2017) discuss peritoneal dialysis-related complications post-renal transplantation, illustrating the complex interplay between dialysis modality, infection risk, and immune status.

Other sources in the vetted list address dialysis complications broadly but do not focus specifically on mRNA vaccines or infection prevention.

Caveats and uncertainty

Most data on mRNA vaccine efficacy in dialysis patients derive from observational cohorts with limited sample sizes.

Durability of protection against emerging SARS-CoV-2 variants remains uncertain in this population.

The impact of vaccination on clinical endpoints such as hospitalization and mortality in dialysis patients requires further prospective study.

Potential vaccine-related adverse events, including rare ocular complications, warrant ongoing surveillance.

Differences between peritoneal and hemodialysis populations in vaccine response and infection risk need clarification.

How this may change practice

Routine administration of mRNA SARS-CoV-2 vaccines should be prioritized in dialysis patients to mitigate infection-related complications.

Clinicians should counsel patients on the benefits and limitations of vaccination, emphasizing continued adherence to infection control measures.

Monitoring antibody responses and considering booster doses may optimize individual protection.

Integration of vaccination strategies into dialysis care protocols can reduce infection burden and improve outcomes.

Further research is needed to guide personalized vaccination schedules and address safety concerns in this group.


References

  1. Quiroga B, et al. Long-Term Dynamic Humoral Response to SARS-CoV-2 mRNA Vaccines in Patients on Peritoneal Dialysis. Vaccines. 2022; DOI:10.3390/vaccines10101738
  2. Levy J, et al. Complications of ESKD: infection. Oxford Handbook of Dialysis. 2016; DOI:10.1093/med/9780199644766.003.0013
  3. Yu J, et al. Varicella-Zoster Virus Infection and Varicella-Zoster Virus Vaccine-Related Ocular Complications. Vaccines. 2025; DOI:10.3390/vaccines13080782
  4. Melexopoulou C, et al. Renal Transplantation in Peritoneal Dialysis Patients: Peritoneal Dialysis related complications in the immediate post-transplant period. 2017; DOI:10.26226/morressier.59a56f96d462b8028d895d90

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team